Type 2 diabetes
Conditions
Interventions
Experimental group:On the basis of the original concomitant medication, we will continue to add hengagliflozin tablets 10mg once a day orally
Sponsors
The First Affiliated Hospital of Xinxiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: type 2 diabetes mellitus; diabetic nephropathy; The diagnostic criteria for type 2 diabetes and diabetic nephropathy are based on the Chinese Guidelines for the Prevention and Treatment of Diabetes 2024 Edition; Age 18-75 years; glomerular filtration rate >45 mL/min/1.73 m^2; urine albumin excretion rate > 30 mg/24 hours (or urine albumin/creatinine ratio (UACR) >=30 mg/g); glycosylated hemoglobin 6.0-8.0%; Fasting blood glucose: 6.0-8.0mmol/L; Postprandial blood glucose: 6.0-11.0mmol/L; The course of the disease >=half a year, and the diet and exercise intervention was not less than 3 months.
Exclusion criteria
Exclusion criteria: Severe liver disease, anemia, heart failure; uncontrolled emerging infectious disease; Cardiovascular and cerebrovascular diseases in the past six months; In patients with uncontrolled hypertension, blood pressure >=140/90mmHg; Current use of ACE inhibitors or ARB class antihypertensive agents; use of diuretics; presence of orthostatic hypotension; Presence of obstructive nephropathy or uncontrolled urinary tract infection; Previous history of complicated urinary tract infection; Glomerular filtration rate 400ml or blood transfusion in the past 3 months; History of alcohol and drug abuse within 1 year; Those who have had severe hypoglycemia or grade 2 hypoglycemic events within half a year; Patients with confirmed primary aldosteronism; Patients with confirmed aldosteronoma; Patients with confirmed renal artery stenosis; Patients with hypertension and severe hypokalemia in the past; Poor compliance; Those who are bedridden or physically disabled and unable to cooperate with the clinical study; Those who are allergic to the active ingredient of hengagliflozin or any excipients; Contraindicated in patients with severe renal impairment, end-stage renal disease, or requiring dialysis; Traditional medications judged by the investigator to potentially affect the activity of the RAAS system; Other investigators judge that they are not suitable to participate in clinical studies; Other use of other drugs confirmed by the investigator to have an impact on the safety and evaluation of the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary angiotensinogen;Plasma renin-angiotensin II.-aldosterone; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fasting cortisol;24h urine sodium;24h urine glucose; | — |
Countries
China
Contacts
Public ContactWang Tao
The First Affiliated Hospital of Xinxiang Medical University
Outcome results
None listed